The dynamic advancements in artificial intelligence are enabling the integration of machine learning into medical practice. A significant challenge in modern anesthesiology is the need for precise, continuous adjustment of anesthetic drug doses in response to the patient's rapidly changing physiological state. Traditional manual methods of drug delivery often result in excessive variability in the depth of anesthesia and hemodynamic stability. Utilizing machine learning algorithms represents a modern, promising approach designed to enhance the overall quality and safety of anesthetic care. Aim of the study: The objective of this study is to review the current state of knowledge concerning machine algorithms in automated anesthetic drug delivery systems and to compare these with conventional administration methods, evaluating the benefits and limitations of each approach. Materials and methods: A review of selected literature in the PubMed, Google Scholar database was conducted, using the following keywords: “anesthetic drugs”, “machine learning”, “closed-loop system” “artificial intelligence” Conclusions: The review demonstrates that Machine Learning-driven Closed-Loop Anesthesia Delivery Systems (CLADS) offer superior stability of anesthetic depth and hemodynamic control compared to manual administration. The implementation of AI allows for the personalization of therapy and a significant reduction in drug and gas wastage, supporting the "Green Anesthesia" initiative. Furthermore, automation contributes to better long-term outcomes, such as reduced incidence of postoperative delirium and cognitive dysfunction. However, despite high autonomy, the "human-in-the-loop" paradigm remains essential due to technical artifacts and unforeseen surgical events. Future research should focus on regulatory standardization and the integration of multi-loop systems managing hypnosis, analgesia, and neuromuscular blockade simultaneously.
24 February 2026 in International Journal of Innovative Technologies in Social Science
Modern anesthesia is a high-frequency control problem: clinicians must continuously titrate hypnotics, opioids, fluids, and vasopressors to achieve adequate hypnosis/analgesia while avoiding hemodynamic instability and downstream organ injury. Artificial intelligence (AI), machine learning, and classical control engineering are increasingly embedded in perioperative monitors and drug delivery platforms, enabling decision support and closed-loop control. Randomized trials and meta-analyses indicate that closed-loop systems for hypnosis (typically processed EEG targets such as BIS) improve time-in-target and reduce overshoot/undershoot compared with manual titration. Multi-variable systems that co-manage hypnosis, analgesia, and fluids are feasible and may improve short-term recovery outcomes in selected settings. On the hemodynamic side, intraoperative hypotension is common and associated with myocardial and kidney injury, AI-based early warning systems using arterial waveforms can predict hypotension minutes before onset and, when paired with treatment protocols, may reduce hypotension burden in some trials. Closed-loop vasopressor and fluid systems improve protocol adherence and reduce hypotension in perioperative and early postoperative care. AI-enabled decision support and closed-loop controllers can improve stability of anesthesia and blood pressure management, but they should be implemented as supervised systems with clear safety constraints, manual override, and ongoing performance monitoring. Future multicenter trials should prioritize patient-centered outcomes, external validation, and transparent reporting.
Introduction: Parkinson’s Disease (PD) and Essential Tremor (ET) are the two most prevalent movement disorders, with tremor being a core, often drug-refractory, motor feature. While traditional surgical treatments like Deep Brain Stimulation (DBS) and Radiofrequency (RF) ablation are effective, they are invasive and carry inherent risks such as hemorrhage and infection, necessitating craniotomy. This reality drives the need for less invasive therapeutic options for patients with advanced, medication-refractory symptoms and motor fluctuations. Aim: The aim of this systematic review is to assess the clinical efficacy and safety profile of Thalamotomy and Pallidotomy performed using Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) technology in the treatment of Essential Tremor and Parkinson’s Disease. Review methods: A comprehensive analysis of research papers available on PubMed and Google Scholar was conducted using keywords: Focused Ultrasound (FUS), Essential Tremor (ET), Parkinson's Disease (PD), Thalamotomy, Pallidotomy, MRgFUS. Conclusion: MRgFUS-guided thalamotomy (VIM) and pallidotomy (GPi) constitute a breakthrough, non-invasive alternative to traditional surgical ablations. The technology demonstrates high and durable efficacy, achieving a 47% reduction in ET tremor and a 39,1% reduction in PD motor symptoms (UPDRS III), comparable to invasive standards. Crucially, MRgFUS offers a favorable safety profile by eliminating the risk of surgical bleeding and infection while providing real-time lesion monitoring. However, a key limitation remains the requirement for an adequate Skull Density Ratio (SDR), excluding some clinically eligible patients. Further long-term, prospective studies are required to fully establish its role.
20 February 2026 in International Journal of Innovative Technologies in Social Science
Non-medical use of anabolic-androgenic steroids (AAS) has expanded beyond elite sports and is common among recreational strength trainees. Chronic supraphysiologic exposure is associated with adverse cardiovascular (CV) remodeling, accelerated atherosclerosis, and excess mortality. This review synthesizes evidence on AAS-associated CV toxicity and proposes a pragmatic diagnostic approach. Current data describe distinct clinical features in users: (i) often reversible cardiometabolic disturbances (dyslipidaemia, hypertension), (ii) structural remodeling, notably concentric left ventricular hypertrophy, (iii) impaired global longitudinal strain that can persist years after cessation, and (iv) premature coronary plaque burden linked to cumulative lifetime exposure. Furthermore, cardiac PET/CT studies indicate persistent coronary microvascular dysfunction, while registry cohorts confirm increased CV disease rates. Consequently, AAS use should be considered a major, under-recognized CV risk factor. We propose a phenotype-based assessment integrating non-judgmental history-taking, athlete-specific ECG interpretation, echocardiography with strain, and selective use of CMR and CCTA. Management should prioritize cessation support, harm reduction, and guideline-directed therapy tailored to the specific clinical phenotype (e.g., cardiomyopathy or coronary disease).
2 March 2026 in International Journal of Innovative Technologies in Social Science
Introduction: Bruxism is currently understood as a range of jaw muscle activities and teeth contact that occur during sleep and/or wakefulness. Awake bruxism can be distinguished from sleep bruxism based on differences in etiology, comorbidities, and the spectrum of muscle activity and clinical manifestations. Although the exact cause of bruxism remains unclear, it is considered to be multifactorial. This article aims to highlight both awake and bruxism and explore various approaches to their management. Aim of the Study: The aim of this article is to review current knowledge on awake and sleep bruxism and increase awareness of its multidisciplinary management. Materials and Methods: A literature review was conducted using the PubMed and Google Scholar databases. The following keywords were used in various combinations: "bruxism," "awake," "sleep" "management," "treatment," and "oral health." Fourty four relevant articles published between 2001 and 2025 were selected for analysis. Results: The most common current approaches to managing awake and sleep bruxism include occlusal splints, mandibular advancement devices, cognitive-behavioral therapy (CBT), biofeedback therapy, mindfulness techniques, self-awareness and self-regulation strategies, physical therapy (such as physiotherapy, exercise, and dry needling), botulinum toxin injections, and non-steroidal anti-inflammatory drugs (NSAIDs) for pain exacerbation. Conclusion: Bruxism and its associated symptoms can significantly affect patients' quality of life. Early identification and appropriate management can help reduce facial muscle soreness, headaches, and general fatigue and pathological tooth wear.
Drug-resistant epilepsy (DRE) is a neurological condition, defined as a failure to make the patient seizure free, after the use of two tolerated, appropriately chosen antiepileptic drugs (AED). Although there is an increasing number of available antiepileptic drugs, it is estimated that pharmacotherapy remains ineffective in approximately 30% of patients. Drug-resistant epilepsy is considered as one of the greatest challenges in modern neurology that affects millions of patients worldwide, who do not respond to standard treatments. Even though epilepsy is one of the most common neurological diseases, with a global total of 50 million people suffering from the condition, treatment of its resistant forms remains complicated and often ineffective. Chronic epileptic seizures can cause serious health problems, limiting patients' mobility, affecting quality of life and increasing the risk of emotional disorders such as depression and anxiety. In response to this challenge, the development of modern drugs for drug-resistant epilepsy has become a medical priority. In recent years, there has been growing interest in new medications such as Cenobamate, Fenfluramine and Cannabidiol, which have different mechanisms of action and promising results in reducing the seizure frequency. Before diagnosing DRE, it is essential to exclude the pseudo-resistance, which may result from different factors such as inadequate doses of medicine, choosing the incorrect medications, or patient-related errors (poor compliance).